EDITORIAL

Should ‘typical’, first-generation antipsychotics no longer be generally used in the treatment of schizophrenia?

Stefan Leucht1 · Maximilian Huhn2 · John M. Davis3,4

Published online: 29 September 2021
© The Author(s) 2021

Since the reintroduction of clozapine in many countries after the landmark trial by Kane et al. in 1988 [1], there are, to date, 16 second-generation, ‘atypical’ antipsychotics in the United States and/or in Europe. The World Health Organization currently lists an additional 52 antipsychotic drugs which are usually classified as first-generation or ‘typical’ [2]. In the 1990s and 2000s, there was a heated debate as to whether the much more costly, second-generation antipsychotics should be preferred to the cheaper first-generation drugs. The essential conclusion of this debate was that overall SGAs produce fewer movement disorders but more weight gain than FGAs, and that some SGAs were somewhat more efficacious than FGAs. However, there are too many exceptions from this rule (e.g. the FGA thioridazine produces very few movement disorders while the SGA risperidone produces a considerable amount, ziprasidone does not produce significant weight gain while chlorpromazine does) for this classification to be valid. Therefore, the misleading and wrong ‘typical’/FGA versus ‘atypical’/SGA distinction has been abandoned and replaced by the Neuroscience-Based Nomenclature [3] which classifies drugs according to their primary mechanism of action.

A decade later, many of the second-generation antipsychotics have lost their patent protection and are available as cheaper generics. One may thus ask whether we should not abandon FGAs altogether? The answer is, it depends on the drug.

On the one hand, the cost debate is not over everywhere. For example, one dose of olanzapine 10 mg i.m. costs 30€ in contrast to only 3€ for haloperidol 5 mg i.m. in Germany, and in developing countries much smaller differences may be important. Thus, FGAs are necessary for medico-economic reasons in many countries and haloperidol, chlorpromazine and fluphenazine together with risperidone and clozapine are on the WHO’s list of essential drugs [4]. This list presents drugs which should be available as a minimum in every country.

On the other hand, it needs to be emphasised that the older drugs have not been nearly as well studied as the newer drugs. When we examined multiple first-generation antipsychotics in our recent network meta-analyses on the acute treatment and the maintenance treatment of schizophrenia [5, 6], it turned out that for almost all FGAs, the number of trials and patients randomised were so small that even if they were combined in one trial they would nowadays not fulfill the criteria of a power calculation (see also Samara et al. [7] which compared chlorpromazine with any other FGA and found that almost all comparisons were underpowered). In the acute-phase network meta-analysis, the confidence in the evidence was very low to low for most first-generation antipsychotics. Indeed, for most FGAs, many of the 13 outcomes chosen for our meta-analysis were not analysed in a single trial. This finding is illustrated by the white bars in Fig. 1 which show the percentage of the 13 outcomes analysed in Huhn et al. [5] for which not a single trial was available.

Therefore, although some of these drugs have been available for more than 50 years, we know much less about them than about SGAs, and most of them would nowadays not be licensed by current standards. This lack of evidence can have consequences for patients. Thioridazine was used a lot in elderly patients until it turned out in studies on second-generation antipsychotics in the 1990s that it is the antipsychotic

---

1 Section for Evidence Based Medicine in Psychiatry and Psychotherapy, Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Ismaninger Straße, 22, 81675 Munich, Germany

2 Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Social Foundation Bamberg, Teaching Hospital of the University of Erlangen, Erlangen, Germany

3 Psychiatric Institute, University of Illinois at Chicago, Chicago, IL, USA

4 Department of Psychiatry, John Hopkins University, Baltimore, MD, USA
associated with most QTc prolongation. The most notable exception is haloperidol which was the gold-standard comparator in trials on second-generation antipsychotics and is, therefore, among the best examined antipsychotics. Thus, haloperidol is and will remain a standard antipsychotic. Another example is perphenazine, a FGA which was used more frequently than haloperidol in some Northern European countries in the “pre-atypical” era. Perphenazine was the comparator FGA in the large, industry-independent CATIE study in which it turned out to be as good if not better than several second-generation antipsychotics [8, 9].

We conclude that with few exceptions, SGAs should be preferred to most FGAs unless medico-economic reasons preclude the use even of SGA generics. Having said this, some of the older drugs have interesting properties such as unique receptor binding profiles. These FGAs might thus offer real clinical advantages and be cost effective if they were well studied. In our next editorial, we will, therefore, discuss which FGAs deserve to be studied further with the aim of “resuscitating” them for practice.

Funding  Open Access funding enabled and organized by Projekt DEAL.

Declarations

Conflict of interest  In the last 3 years, SL has received honoraria as a consultant and/or advisor and/or for lectures from Alkermes, Angelini, Eisai, Gedeon Richter, Janssen, Johnson and Johnson, Lundbeck, Medichem, Merck Sharp and Dome, Otsuka, Recordati, Rovi, Sandoz, Sanofi Aventis, Sunovion, TEVA, and Medichem. MH has received honoraria as advisor from Recordati. JMD has no conflict of interest to declare.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Kane JM, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789–796
2. WHO (2012) Collaborating centre for drug statistics methodology. ATC index with DDDs. WHO, Oslo
3. Zohar J, Stahl S, Moller HJ et al (2015) A review of the current nomenclature for psychotroic agents and an introduction to the Neuroscience-based Nomenclature. Eur Neuropsychopharmacol 25(12):2318–2325
4. World Heath Organisation (2009) Essential drugs. WHO Drug Inform 13(4):249–262
5. Huhn M, Nikolakopoulou A, Schneider-Thoma J et al (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394(10202):939–951
6. Schneider-Thoma J, Chalkou K, Dörries C, et al. (2021) Comparative efficacy and tolerability of 31 oral and depot antipsychotics for maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet. In press

7. Samara MT, Cao H, Heller B, Davis JM, Leucht S (2014) Chlorpromazine versus every other antipsychotic for schizophrenia: a systematic review and meta-analysis challenging the dogma of equal efficacy of antipsychotic drugs. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 24(7):1046–1055

8. Lieberman JA, Stroup TS, McEvoy JP et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12):1209–1223

9. Keefe RSE, Bilder RM, Davis SM et al (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 64(6):633–647